Search Within

David H Ilson

  1. "Gastrointestinal Oncology Service"
Formats
  1. Journal Article (209)
  2. Meeting Abstract (168)
  3. Book Section (20)
  4. Review (13)
  5. Editorial (9)
  6. Conference Paper (6)
  7. Guidelines (3)
  8. Correspondence (2)
  9. Book Whole (1)
  10. Miscellaneous (1)
  11. Research Letter (1)
Groups
  1. Department of Medicine (433)
  2. Gastrointestinal Oncology Service (433)
  3. Solid Tumor Oncology Division (433)
  4. Center for Pancreatic Cancer Research (186)
  5. Surgery (136)
  6. Survivorship Research (127)

More Groups

People
  1. David Kelsen (132)
  2. Geoffrey Ku (122)
  3. Yelena Janjigian (111)
  4. Marinela Capanu (65)
  5. Laura Tang (60)
  6. Manjit Bains (51)

More People

Years
  1. 2025 (5)
  2. 2024 (16)
  3. 2023 (24)
  4. 2022 (21)
  5. 2021 (22)
  6. 2020 (20)

More Years

Publications
  1. Journal of Clinical Oncology (135)
  2. Annals of Oncology (28)
  3. International Journal of Radiation Oncology, Biology, Physics (15)
  4. Journal of the National Comprehensive Cancer Network (14)
  5. Annals of Surgical Oncology (13)
  6. Cancer (12)

More Publications

Publishers
  1. American Society of Clinical Oncology (137)
  2. Elsevier Inc. (57)
  3. Oxford University Press (41)
  4. Springer (32)
  5. Lippincott Williams & Wilkins (22)
  6. Wiley Blackwell (18)

More Publishers

Results (433)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Metastatic esophagogastric cancer
    Book Section

    Ku, G. Y.; Ilson, D. H.
    In Abutalib, S. A.; Markman, M.; Benson, A. B. 3rd; Rugo, H. S. (Eds.) Cancer Consult: Expertise in Clinical Practice. 2nd ed (2024)

    Fulltext@MSK | Save
  • Updated efficacy and safety results from phase III GLOW study evaluating zolbetuximab plus CAPOX as first-line (1L) treatment for patients with claudin-18 isoform 2-positive (CLDN18.2+), HER2— , locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma
    Meeting Abstract

    Lordick, F.; Shah, M. A.; Shitara, K.; Ajani, J. A.; Bang, Y. J.; Enzinger, P. C.; Ilson, D. H.; van Cutsem, E.; Gallego Plazas, J.; Huang, J.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Zolbetuximab+mFOLFOX6 as first-line (1L) treatment for patients (Pts) with claudin-18.2+(CLDN18.2+) / HER2-locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma: Primary results from phase 3 SPOTLIGHT study
    Meeting Abstract

    Lordick, F.; Shitara, K.; Bang, Y. J.; Enzinger, P.; Ilson, D.; Shah, M. A.; Van Cutsem, E.; Xu, R. H.; Aprile, G.; Xu, J.; more...
    Oncology Research and Treatment (2023)

    Fulltext@MSK | Save
  • Zolbetuximab + CAPOX in 1L Claudin-18.2+(CLDN18.2+)/HER2-locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma: Primary phase 3 results from GLOW
    Meeting Abstract

    Lordick, F.; Xu, R. H.; Shitara, K.; Ajani, J. A.; Bang, Y. J.; Enzinger, P.; Ilson, D.; Van Cutsem, E.; Plazas, J. G.; Huang, J.; more...
    Oncology Research and Treatment (2023)

    Fulltext@MSK | Save
  • Updated efficacy and safety results from phase III GLOW study evaluating zolbetuximab + CAPOX as first-line (1L) treatment for patients with claudin-18 isoform 2-positive (CLDN18.2+), HER2–, locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma
    Meeting Abstract

    Lordick, F.; Shah, M. A.; Shitara, K.; Ajani, J. A.; Bang, Y. J.; Enzinger, P. C.; Ilson, D. H.; Van Cutsem, E.; Plazas, J. G.; Huang, J.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Updated efficacy and safety results from phase III SPOTLIGHT study evaluating zolbetuximab + mFOLFOX6 as first-line (1L) treatment for patients with claudin-18 isoform 2-positive (CLDN18.2+), HER2–, locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma
    Meeting Abstract

    Ajani, J. A.; Lordick, F.; Bang, Y. J.; Enzinger, P. C.; Ilson, D. H.; Shah, M. A.; Van Cutsem, E.; Xu, R. H.; Aprile, G.; Xu, J.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Prognostic value of circumferential radial margin involvement in esophagectomy for esophageal cancer: A case series
    Journal Article

    Boerner, T.; Carr, R.; Hsu, M.; Tan, K. S.; Sigel, C.; Tang, L.; Harrington, C.; Ku, G. Y.; Ilson, D. H.; Janjigian, Y. Y.; more...
    International Journal of Surgery (2023)

    Fulltext@MSK | Save
  • Neoplasia risk in patients with Lynch syndrome treated with immune checkpoint blockade
    Journal Article

    Harrold, E. C.; Foote, M. B.; Rousseau, B.; Walch, H.; Kemel, Y.; Richards, A. L.; Keane, F.; Cercek, A.; Yaeger, R.; Rathkopf, D.; more...
    Nature Medicine (2023)

    Fulltext@MSK | Save
  • First-line regorafenib with nivolumab and chemotherapy in advanced oesophageal, gastric, or gastro-oesophageal junction cancer in the USA: A single-arm, single-centre, phase 2 trial
    Journal Article

    Cytryn, S. L.; Moy, R. H.; Cowzer, D.; Shah, R. H.; Chou, J. F.; Joshi, S. S.; Ku, G. Y.; Maron, S. B.; Desai, A.; Yang, J.; more...
    Lancet Oncology (2023)

    Fulltext@MSK | Save
  • Advances in the treatment of gastric cancer: 2022-2023
    Review

    Ilson, D. H.
    Current Opinion in Gastroenterology (2023)

    Fulltext@MSK | Save